Literature DB >> 16041607

Contribution of combined colposcopy and cytology in cervical pathology.

D Tamiolakis1, M Kalloniatou, M Lambropoulou, M Kambanieris, A Tsopelas, G Daskalakis, S Nikolaidou, I Venizelos, N Papadopoulos.   

Abstract

AIM: The regular Papanicolaou (Pap) smear is the cornerstone of women's preventive healthcare. The introduction of the regular Pap smear as a screening tool for cervical cancer has markedly decreased the number of deaths from cervical cancer. During the past decade, however, the rate of death from cervical cancer has remained relatively static. This screening method is known to have a high percentage of false negative results. To improve the detection of cervical lesions using the Pap smear in screening, a number of adjunct procedures have been developed. The purpose of this study is to evaluate the utility of a magnified chemoluminescent screening examination (Colposcopy) combined with the Pap smear in detecting cervical abnormalities.
METHODS: We investigated a cohort of 58 subjects who have been forwarded for colposcopic evaluation due to referral cytology suggestive of persistent inflammatory process not otherwise specified, and cervical intraepithelial or invasive neoplasia, in Chania Colposcopic clinic.
RESULTS: The higher the lesion detected by cytology, the more severe the corresponding colposcopic impression viewed.
CONCLUSION: The data presented here are in harmony with previous reports and share our experience in a Regional Community Hospital Colposcopy Clinic. An integrated cytology-colposcopy program facilitates the assessment and identification of women harboring cervical pathological conditions.

Entities:  

Mesh:

Year:  2005        PMID: 16041607     DOI: 10.1007/s00404-005-0018-x

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  1 in total

1.  Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.

Authors:  Jiexian Jing; Shumin Zheng; Cunzhi Han; Lili Du; Yongfeng Guo; Pei Wang
Journal:  J Clin Lab Anal       Date:  2012-01       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.